Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930035/S036

Wrench Kit Model 6501

Boston Scientific · Decision date Apr 10, 2026

FDA DECISIONP930035/S036

What did the FDA approve?

FDA records P930035/S036 as a supplement to PMA P930035, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 10, 2026.

FDA approval order statement

approval for minor labeling changes, removal of paper IFU, and minor dimensional changes to sterile pouches
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Apr 10, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P930035/S036
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Apr 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P930035/S036 received

    Application receipt date recorded by FDA.

  2. P930035/S036 · FDA decision

    Real-Time Process

  3. P930035/S037 · Related supplement

    Hex Wrench (#2) (Model 6501)

Timeline entries are records held by MedtechLedger for P930035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P930035

Product / regulatory recordCompanyPathwayDecision dateSource
ACC WRENCHP930035/S035
Boston ScientificPMA supplementSep 16, 2025FDA
Boston ScientificPMA supplementMay 15, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records